VITA 34 AG (DE:V3V)
XETRA:V3V
Want to see DE:V3V full AI Analyst Report?
Top Page
VITA 34
(XETRA:V3V)
Select Model
Select Model
Rating:43Neutral
Price Target:
€4.50
▼(-25.62% Downside)
Action:ReiteratedDate:05/04/26
The score is primarily held down by weak financial performance: persistent losses, a shrinking equity base with rising debt, and 2025 revenue contraction (with free cash flow turning slightly negative). Technicals are also bearish with the stock below major moving averages, partly offset by oversold RSI/Stoch readings. Valuation is only moderate (P/E ~21) without dividend support.
Positive Factors
Recurring revenue model
The subscription-like annual storage fees create a durable, predictable revenue base and high customer lifetime value. This recurring cash inflow supports long-term planning, capacity utilization and makes scaling unit economics easier as customer volumes grow over months to years.
Negative Factors
High financial leverage
Elevated leverage increases fixed interest obligations and reduces financial flexibility, limiting the firm's ability to fund capex or weather cyclical slowdowns. Over months, this raises refinancing and solvency risk, particularly if cash generation does not strengthen.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue model
The subscription-like annual storage fees create a durable, predictable revenue base and high customer lifetime value. This recurring cash inflow supports long-term planning, capacity utilization and makes scaling unit economics easier as customer volumes grow over months to years.
Read all positive factors
VITA 34 (V3V) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€77.40M
Dividend YieldN/A
Average Volume (3M)1.65K
Price to Earnings (P/E)21.1
Beta (1Y)0.18
Revenue Growth7.29%
EPS Growth47.59%
CountryDE
Employees783
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.36
Shares Outstanding17,640,104
10 Day Avg. Volume2,079
30 Day Avg. Volume1,645
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€85.00M
VITA 34 Business Overview & Revenue Model
Company Description
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of end...
How the Company Makes Money
null...
VITA 34 Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
34
Negative
Cash Flow
46
Neutral
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.17M | 82.18M | 77.06M | 68.94M | 28.42M |
| Gross Profit | 44.84M | 20.65M | 28.24M | 2.73M | 12.44M |
| EBITDA | 4.76M | -443.00K | 5.81M | -18.34M | 949.00K |
| Net Income | -6.30M | -12.14M | -1.86M | -27.39M | -3.93M |
Balance Sheet | |||||
| Total Assets | 168.26M | 152.74M | 158.36M | 151.51M | 177.95M |
| Cash, Cash Equivalents and Short-Term Investments | 11.88M | 18.46M | 17.42M | 18.23M | 35.26M |
| Total Debt | 23.51M | 18.10M | 21.57M | 28.18M | 32.32M |
| Total Liabilities | 162.84M | 139.83M | 135.58M | 135.66M | 136.00M |
| Stockholders Equity | 7.12M | 14.13M | 23.56M | 16.50M | 43.07M |
Cash Flow | |||||
| Free Cash Flow | -249.00K | 5.46M | 5.06M | -10.92M | 467.00K |
| Operating Cash Flow | 3.88M | 8.65M | 9.15M | -4.49M | 2.73M |
| Investing Cash Flow | -12.66M | -3.08M | -3.57M | -5.81M | 24.87M |
| Financing Cash Flow | 3.89M | -6.09M | -5.09M | -6.27M | -4.70M |
VITA 34 Technical Analysis
Negative
6.05
Price Trends
4.96
Negative
5.34
Negative
5.51
Negative
Market Momentum
-0.10
Negative
27.96
Positive
29.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Negative. The current price of 6.05 is above the 20-day moving average (MA) of 4.71, above the 50-day MA of 4.96, and above the 200-day MA of 5.51, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 27.96 is Positive, neither overbought nor oversold. The STOCH value of 29.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:V3V.
VITA 34 Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €160.55M | 6.90 | 10.71% | 1.12% | 4.77% | 2.62% | |
56 Neutral | €349.43M | 23.60 | 2.97% | ― | 10.39% | 19.18% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €213.94M | -1,127.69 | 6.55% | 2.71% | ― | ― | |
43 Neutral | €77.40M | 21.07 | -71.32% | ― | 7.29% | 47.59% |
* General Sector Average
DE:V3V
VITA 34
4.44
0.54
13.85%
DE:MED
MEDICLIN
3.38
0.44
15.01%
DE:SBS
STRATEC Biomedical
17.60
-6.40
-26.67%
DE:ILM1
Medios AG
13.70
1.46
11.93%
DE:HAEK
HAEMATO AG
11.40
-2.65
-18.84%
DE:7V0
Novogenia Holding AG
9.05
2.70
42.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.